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ABSTRACT
IL-2 gene expression in activated T-cells is initiated
by chromatin remodeling at the IL-2 proximal
promoter and conversion of a transcriptional
repressor into a potent transcriptional activator. A
purine-box regulator complex was purified from
activated Jurkat T-cell nuclei based on sequence-
specific DNA binding to the antigen receptor
response element (ARRE)/nuclear factor of acti-
vated T-cells (NF-AT) target DNA sequence in
the proximal IL-2 promoter. ARRE DNA-binding
subunits were identified as NF90, NF45 and systemic
lupus erythematosis autoantigens, Ku80 and Ku70.
Monoclonal antibodies to Ku80, Ku70 and NF90
specifically inhibit constitutive and inducible ARRE
DNA-binding activity in Jurkat T-cells. Ku80, Ku70
and NF90 bind specifically to the IL-2 gene promoter
in vivo, as demonstrated by chromatin immuno-
precipitation. Activation of Jurkat T-cells and
mouse primary spleen cells induces binding of
Ku80 and NF90 to the IL-2 promoter in vivo, and
decreases binding of Ku70 to the IL-2 promoter
in vivo, and these dynamic changes are inhibited
by immunosuppressants cyclosporin A and
triptolide. Dynamic changes in binding of Ku80,
Ku70 and NF90 to the IL-2 proximal promoter
in vivo correlate with chromatin remodeling and
transcriptional initiation in activated T-cells.
INTRODUCTION
Expression of T-cell growth factor, IL-2, is tightly
regulated. Activation of T-cells through the T-cell antigen
and CD28 coreceptors signals up to a 100-fold increase in
IL-2 mRNA expression within 6hr followed by protein
secretion (1). IL-2 gene expression in activated T-cells
involves chromatin remodeling at the IL-2 proximal
promoter that is closely linked to cooperative binding of
transcription factors to the antigen receptor response
element (ARRE)/nuclear factor of activated T-cells
(NF-AT), NF-kB, AP-1 and Oct-1 sequences and intense
transcriptional activation (2). The A-T-rich purine-box/
ARRE/NF-AT target site serves a unique role in
regulating IL-2 transcription: a speciﬁc transcriptional
repressor preexisting in resting T-cells is converted during
T-cell activation into a potent transcriptional activator,
through mechanisms that involve melting of chromatin
(2–4). Proteins are prebound to the distal ARRE/NF-AT
site in the IL-2 promoter in the nucleus of resting
Jurkat and EL-4 T-cells and T-cell activation triggers
expansion of the footprint of this purine-box regulator
complex (5,6).
We previously described the puriﬁcation from stimu-
lated Jurkat T-cells of an inducible nuclear purine-box
regulator that binds speciﬁcally to the ARRE/NF-AT
target DNA sequence in the IL-2 promoter (7,8). Subunits
of this labile purine-box regulator, NF45 and NF90, are
zinc-ﬁnger DNA- and RNA-binding proteins. NF90
contains two double-stranded RNA-binding domains
(dsRBD) that bind structured RNAs including IL-2
(9,10). Antisera to NF90 and NF45 speciﬁcally inhibited
ARRE/NF-AT DNA-binding and in vitro transcription
(7). NF45 and NF90 regulate transcriptional activation of
the IL-2 promoter and other genes (11–14), posttranscrip-
tional mRNA stabilization and nuclear export of IL-2
and other genes (9,10) and translation (15,16). NF90 has
been implicated in host antiviral responses and as a
cellular cofactor involved in viral replication and transla-
tion (16–18). Targeted disruption of NF90 is associated
with profound T-cell lymphocytopenia, severe impairment
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tional activation (Shi et al, J. Exp Med. in press).
Here we report that systemic lupus erythematosis
autoantigens, Ku80 and Ku70, copurify with NF90
and NF45, and contribute to speciﬁc binding of the
purine-box regulator to ARRE/NF-AT DNA sequences
in vitro and to the IL-2 promoter in vivo (20,21). Ku80 and
Ku70 are multifunctional nucleic acid binding proteins
that interact with double- and single-stranded DNA
and RNA (22). In complex with the catalytic subunit of
DNA-dependent protein kinase (DNA-PKcs), Ku80 and
Ku70 participate in repair of double-stranded DNA
breaks and in V(D)J recombination in lymphocytes
(23,24). Ku80 and Ku70 bind speciﬁcally to purine-rich
and A-T rich DNA sequences and regulate transcription
(25–34), and mammalian DNA, HIV and HSV replication
(29,35–39).
We present complementary experiments of protein
puriﬁcation, Electrophoretic mobility shift assays
(EMSA)-antibody inhibition and chromatin immunopre-
cipitation that demonstrate speciﬁc binding of Ku80,
Ku70 and NF90 to ARRE DNA-sequences in vitro
and dynamic binding to the proximal IL-2 promoter
in vivo.
MATERIALS AND METHODS
Cell cultureand stimulation conditions
Jurkat T-cells were nonstimulated (NS) or stimulated
for 4hr with phorbol myristyl acetate (20ng/ml)
and ionomycin (2mM), in the absence or presence of
cyclosporin A (1000ng/ml) or triptolide (200 or
1000ng/ml, PG490, Pharmagenesis, Palo Alto, CA).
Electrophoretic mobility shiftassays (EMSA)
Nuclear proteins (5 mg) were incubated with
32P-labeled
oligonucleotide probe for 30min at 48C [25mM HEPES
pH 7.6, 50mM KCl, 0.1mM EDTA, 10% glycerol and
1.5mg poly(dI-dC)]. The poly(dI-dC) was included as a
nonspeciﬁc competitor and a source of free DNA ends.
The amount of poly(dI-dC) was adjusted during the
puriﬁcation steps to reveal speciﬁc ARRE DNA-binding
complexes in the presence of excess free probe. Protein–
DNA complexes were separated on 4% nondenaturing
acrylamide gels in 0.5  Tris–Borate EDTA. The wild-type
ARRE-2 oligonucleotide probe is 50 gatcGGAGGAAAA
ACTGTTTCATACAGAAGGCGT-30 (–255 to –285 in
the human IL-2 promoter), and the mutant ARRE-2
competitor oligonucleotide is 50-gatcGAAAGGAGtAAA
AAaTtTTTaATACAGAA-30 (7). The NF-kB probe is
50 agctAAAGAGGGACTTTCCCTAAA-30. For EMSA-
antibody inhibitions, 2ml of ascites or 200–250ng of
puriﬁed mAB or polyclonal antisera were incubated with
nuclear proteins for 30min at 48C before addition of
radiolabeled probe and further incubation.
Antibodies
Anti-human Ku monoclonal antibodies used for EMSA
were mAB162 (anti-Ku heterodimer), 111 (Ku80) and
N3H10 (Ku70) (Becton–Dickinson and Neomarkers) (40).
Other antibodies used for EMSA, Western and ChIP:
Ku80 (Santa Cruz sc-1485), Ku70 (sc-1486), NF90 (mAB
DRBP76 BD), NFATp (sc-1151), NFATc1 (mAB clone
7A6, sc-7294), NFATc2 (mAB clone G1-D10, sc-7295)
and cPLA2 (sc-438).
Proteinpurification
Jurkat T-cells were stimulated for 12hr with 20ng/ml
PMAþ2 mM ionomycin. Nuclear proteins were extracted
from chromatin with 0.3M ammonium sulfate for 30min
at 48C and the supernatants were precipitated with 0.2g/
ml ammonium sulfate. The protein pellets were resus-
pended in buﬀer C25 (25mM HEPES, pH 7.6, 25mM
KCl, 0.1mM EDTA, 1mM DTT, 10% glycerol) and
dialyzed against two changes of C25. Nuclear proteins
(300mg) were puriﬁed using a diethylaminoethyl column
(Whatman DE-52, 20 2.2cm
2) eluted with a linear
gradient of 25–400mM KCl. Complex I eluted around
200mM KCl, and these fractions were pooled, dialyzed
against C25 and chromatographed on a carboxymethyl–
agarose column eluted with a gradient of KCl (Pharmacia,
14 2.2cm
2). Complex I eluted around 180mM KCl.
Fractions were pooled and dialyzed against C25 and
loaded onto an octylamine–agarose column (Pharmacia,
5 0.8cm
2) and eluted stepwise with buﬀer C containing
0.1, 0.2, 0.25, 0.3 and 0.4M KCl. Complex I eluted
maximally at 0.2M KCl, and complexes II and III eluted
maximally at 0.4M KCl. Octylamine fraction 0.2 contain-
ing complex I (pool A) was adjusted to 50mM KCl and
coupled to a mutant or wild-type ARRE oligonucleotide
aﬃnity column (200ml volume) (7). The aﬃnity columns
were washed with buﬀer C50 and eluted stepwise with
three column volumes each of buﬀer C containing 0.1,
0.2, 0.3 or 0.4M KCl. Complex I eluted at 0.2M KCl
with better recovery from the mutant compared to the
ARRE aﬃnity column. Complexes II and III present in
octylamine 0.4M fraction (pool B) were diluted to 50mM
KCl and applied to a wild-type ARRE aﬃnity column.
Complex II/III peak activity eluted maximally from the
ARRE column at 0.4M KCl.
Coimmunoprecipitation studies
NF45 IgG was covalently coupled to protein-A agarose
using bis(sulfosuccinimidyl)suberate (BS
3, Pierce). Jurkat
T-cells (1–2 10
7cells/condition) were either nonstimu-
lated, stimulated with PMAþionomycin or stimulated
in the presence of CsA (1000ng/ml) or triptolide
(1000ng/ml), and then nuclear extracts were prepared.
Immunoprecipitations were performed by incubating
150mg of Jurkat T-cell nuclear proteins with 50mlo f
protein A beads (control) or anti-NF45-protein A beads
for 2hr at 48C, and then washing 4  with 200mlo f
intermediate stringency buﬀer (50mM Tris–Cl pH 7.5,
250mM NaCl, 1% NP-40, 0.1% SDS). The speciﬁc
immunoprecipitates were fractionated by SDS–PAGE
(8% separating gel), and proteins were transferred to
nitrocellulose using a semidry blotter (BioRad). Primary
antibodies for Western immunoblotting were goat aKu70
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Chromatin immunoprecipitation
Jurkat T-cells or C57BL/6 mouse primary spleen cells
were nonstimulated or stimulated for 4hr with
PMAþionomycin, in the absence or presence of CsA
(1000ng/ml) or triptolide (200ng/ml), then formaldehyde
crosslinking and chromatin immunoprecipitation (ChIP)
was performed as described (36). PCR primers were
designed to amplify the human IL-2 promoter: F 50-GAG
TTACTTTTGTATCCCCACCCCC (–317 to –292 in the
IL-2 promoter), R 50-CCTGTACATTGTGGCAGGAGT
TGAGG (þ33 to 58); IL-2 intron 3: F 50-GCTTAAGAG
GATACAGAACACTGCAACAG, R 50-CCCTACCCC
ATCATAGTATCAATGCAGGTG; origin negative
control myc1: F 50-TTCTCAACCTCAGCACTGG
TGACA, R 50-GACTTTGCTGTTTGCTGTCAGGCT;
myc11 origin of replication: F 50-TATCTACACTAACAT
CCCACGCTCTG, myc11: R 50-CATCCTTGTCCTGTG
AGTATAAATCATCG. Mouse PCR primers were: IL-2
proximal promoter (270bp): F 50-CTGCCACCTAAGTG
TGGGCTAACCCGACC, R 50-GCATGCTGTACATG
CCTGCAGGACTTGAGG; IL-2 intron 3 (424bp): F
50-CCACAATGTGGGTGGGTCACTGCAATTGAAC,
R5 0-GTTAGGCCACTCTAGTGAGCTCTTCTGGC;
adenosine deaminase origin of DNA replication
(268bp): F 50-CTGAGACTATCCTCCAGGTCTTCTA
ATGGGG, R 50-GGATGACCCTTTCATGGCTGCCT
ATGACCAACAG. PCR ampliﬁcations used a three-step
protocol with 598C annealing temperature and 35 cycles.
RESULTS
Purine-box regulator complexes contain ARRE DNA-
binding subunits NF90, NF45, Ku80 and Ku70
Activated Jurkat T-cells contain an inducible nuclear
purine-box regulator ARRE/NF-AT DNA-binding
complex (Figures 1 and 2) (7,8,20). Purine-box regulator
complex I migrates slowly as an elongated complex in
EMSA and exhibits highly speciﬁc ARRE DNA-binding
activity. At all stages of puriﬁcation complex I converted
into faster migrating complexes II and III that exhibited
tighter bands in EMSA (Figure 1) and this observation
led us to infer that all three complexes might share
common ARRE DNA-binding subunits. The conversion
of complex I into complexes II and III was promoted by
exposure to salt concentrations above 0.4M and to DNA.
We developed a puriﬁcation strategy for complex I that
minimized exposure to high salt and DNA, which
involved sequential diethylaminoethyl (Figure 1A),
Figure 1. Puriﬁcation of purine-box regulator complexes reveals
ARRE–DNA-binding subunits NF90, NF45, Ku80 and Ku70. EMSA
were used to monitor enrichment of ARRE–DNA-binding complexes
from nuclear extracts of Jurkat T-cells stimulated with
PMAþIonomycin. (A) Diethylaminoethyl (DEAE) elution. Fractions
enriched in complex I (and small amounts of complexes II and III)
were pooled and dialyzed. (B) Carboxymethyl (CM) elution. Note the
substantial conversion of complex I into complexes II and III.
Fractions containing complex I only were pooled and dialyzed.
(C) Octylamine elutions with steps of KCl. Right, oligonucleotide
competitions demonstrate greater inhibition of complex I in elution 0.2
with 50ng of wild type (W) compared to mutant (M) ARRE, yet 50ng
of M does produce substantial inhibition of complex I. (D) DNA-
aﬃnity elution. Octylamine elutions 0.2M KCl/pool A, enriched in
complex I only, were diluted and loaded onto a mutant ARRE–DNA-
aﬃnity column and eluted with the indicated steps of KCl. Note the
presence of complexes I and III in eluted fraction 0.2, associated with
principal protein subunits at 45, 80, 90, 130 and 350kDa shown by
SDS–PAGE with silver staining. Ten nanograms of wild-type (W)
ARRE oligonucleotide inhibits complex I and promotes conversion
to complex III more potently than mutant (M) oligonucleotide.
(E) DNA-aﬃnity elution. Octylamine elutions enriched in complexes
II and III, pool B, were diluted and loaded onto a wild-type ARRE–
DNA-aﬃnity column, and maximal DNA-binding activity was eluted
at 0.4M KCl, associated with protein subunits at 70, 80 and 350kDa
shown by SDS–PAGE with silver staining. Internal tryptic peptide
sequences of the 70 and 80kDa proteins identiﬁed them as Ku70 and
Ku80. Western immunoblot with human JM anti-Ku sera (right)
conﬁrms the identity of Ku70 and Ku80 (lane 4), and suggests the
slowest migrating protein to be DNA-dependent protein kinase (DPK)
catalytic subunit.
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ion-exchange columns followed by DNA-aﬃnity chroma-
tography (Figure 1D and E). Complex I was substantially
enriched in the octylamine elution 0.2M KCl/pool
A (Figure 1C). Oligonucleotide competition experiments
demonstrated greater inhibition of complex I binding
using the wild-type compared to the mutant ARRE
sequence (Figure 1C, lanes W versus M). Fifty nanograms
of wild-type ARRE oligonucleotide completely inhibited
complex I binding and promoted conversion of residual
complex I into complex III. In contrast, 50ng of mutant
ARRE oligonucleotide only partially inhibited complex I,
and did not promote conversion of complex I into III.
This result suggested a moderate aﬃnity of complex I for
the mutant ARRE sequence. We successfully employed
an immobilized mutant ARRE aﬃnity column for gentle
puriﬁcation of complex I using elution with low concen-
trations of salt. We loaded octylamine-eluted pool
A containing exclusively complex I (Figure 1C) onto a
mutant ARRE DNA-aﬃnity column (Figure 1D) and
recovered maximal complex I activity at 0.2M KCl,
coeluting with substantial amounts of complex III, and
associated with proteins of 45, 80, 90, 130 and 350kDa
(Figure 1D, right). This result suggested that aﬃnity-
puriﬁed complex I could convert into complex III, and
that complexes I and III might share common ARRE
DNA-binding subunits. Ten nanograms of wild-type
ARRE oligonucleotide completely inhibited complex I
and promoted conversion of complex I into complex III
(Figure 1D, lane W). In contrast, 10ng of mutant ARRE
oligonucleotide was less potent than wild type in inhibiting
complex I formation (hence the residual smear), and less
potent in inhibiting complex III (Figure 1D, lane M).
These EMSA competitions show that complexes I and
III each exhibit greater aﬃnity for the wild-type ARRE
compared to the mutant ARRE oligonucleotide. We
previously characterized the 45 and 90kDa proteins as
NF45 and NF90 (8).
We puriﬁed complexes II and III in octylamine elution
0.4M KCl/pool B (Figure 1C) using a wild-type ARRE
DNA-aﬃnity column (Figure 1E) and determined that
maximal activity eluted at 0.4M KCl. ARRE sequence-
speciﬁc binding was demonstrated by the greater inhibi-
tion of complexes II and III with 50 and 100ng of wild
type compared to mutant competitor oligonucleotides
(Figure 1E, lanes W versus M). Complexes II and III were
associated with proteins of 70, 80 and 350kDa (Figure 1E,
right). Internal tryptic peptide sequence information
allowed us to identify these proteins as the systemic
lupus erythematosis autoantigens, Ku70 and Ku80 (data
not shown). Human anti-Ku serum JM reacted speciﬁcally
with the puriﬁed 70 and 80kDa proteins in a Western
immunoblot (Figure 1E, right, lane aKu). We interpret the
350kDa immunoreactive protein to represent DNA-
dependent protein kinase catalytic subunit (DPKcs),
known to interact with Ku70 and Ku80 (21).
Purine-boxregulator complex in unfractionated nuclear
extracts containsARRE DNA-binding subunits Ku80,
Ku70 andNF90
We proceeded to test whether antibodies against Ku80,
Ku70 or NF90 aﬀected the purine-box regulator/ARRE
DNA-binding complex in nuclear extracts prepared
from resting and activated Jurkat T-cells (Figure 2). In
nonstimulated Jurkat T-cells, a purine-box regulator
complex can be detected in the nucleus (Figure 2A, lane
2), and T-cell activation with PMAþionomycin (P/I)
strongly induces the DNA-binding aﬃnity of this complex
(Figure 2A, lane 6 versus 2). Activation in the presence of
CsA inhibits the induction of ARRE–DNA-binding
activity down to the NS level (Figure 2, lane 11 versus
6). Monoclonal antibodies against the Ku heterodimer,
individual Ku80 or Ku70 subunits (40), each produced
nearly complete inhibition of both the constitutive and
inducible purine-box regulator complex (Figure 2A, lanes
3–5 versus 2 and 7–9 versus 6). We observed no signiﬁcant
inhibition of the purine-box regulator with polyclonal
antibodies against NF-ATp/NFATc2 or unrelated
cytoplasmic phospholipase A2 (Figure 2A, lanes 10 and
12). The absence of a supershift may be a consequence
of the labile nature of the purine-box regulator, and its
dissociation by subunit-speciﬁc antibodies. As a control
for speciﬁcity, the mAbs to Ku caused no inhibition of
the induced NF-kB DNA-binding complex (Figure 2B,
lanes 3–5 versus 2). A mAB to NF90 (anti-DRBP76)
also inhibited the purine-box regulator complex I in
Figure 2. Purine-box regulator in T-cell nuclear extracts contains
ARRE–DNA-binding subunits Ku80, Ku70 and NF90. EMSA of
nuclear proteins from NS and PMAþionomycin (P/I)-stimulated
Jurkat T-cells. (A) Monoclonal antibodies against Ku were preincu-
bated with nuclear proteins before addition of
32P-labeled oligonucleo-
tide probe: 162 recognizes the native Ku70/Ku80 heterodimer, 111
recognizes Ku80 and N3H10 recognizes Ku70. Polyclonal antibodies
against NF-ATp or cytoplasmic phospholipase A2 (cPLA2) did not
inhibit binding of purine-box regulator complex, while cyclosporin A
(CsA) caused partial inhibition. (B) Ku monoclonal antibodies did not
inhibit induced NF-kB DNA-binding. (C) Monoclonal antibodies to
NF90 (mAB anti-DRBP76), Ku80 and Ku70, but not NFATc1 or
NFATc2, speciﬁcally inhibited purine-box regulator ARRE–DNA-
binding activity in nuclear extracts of nonstimulated and P/I-stimulated
Jurkat T-cells.
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polyclonal anti-Ku80 and anti-Ku70 (Figure 2C, lanes
2–4 versus 1 and 9–11 versus 8). Under our experimental
conditions (that used 0.3M ammonium sulfate to extract
nuclear proteins), mAbs against nuclear factor of acti-
vated T-cells, NFATc1 and NFATc2 (characterized to
bind ARRE sequences in vitro following 0.42M KCl
nuclear extractions) did not aﬀect the purine-box reg-
ulator complex I in nonstimulated or stimulated T-cells
(Figure 2C, lanes 5 and 6 versus 1 and 12 and 13 versus 8).
These EMSA-antibody inhibition experiments conﬁrm the
results of our puriﬁcation (Figure 1) and demonstrate that
Ku80, Ku70 and NF90 are speciﬁc ARRE DNA-binding
subunits of the purine-box regulator in nonstimulated and
stimulated T-cell nuclear extracts.
Interactions between Ku, DNA-PK, NF45 andNF90 are
weakenedduring T-cell activation
We characterized T-cell activation-induced changes in
purine-box regulator subunit interactions by coimmuno-
precipitation (Figure 3). Jurkat T-cells were either non-
stimulated, stimulated with PMAþionomycin for 4hr or
stimulated in the presence of immunosuppressants CsA or
triptolide (41). NF45, NF90, Ku80, Ku70 and DNA-PKcs
were readily detected by immunoblotting in nuclear
extract from nonstimulated T-cells (Figure 3, lane 1),
but were not detected in protein A precipitates performed
in the absence of NF45 antibody (Figure 3, lane 2).
Extracted nuclear proteins were immunoprecipitated with
immobilized antibody against NF45 and the immuno-
precipitates (IP) were washed at low, moderate or high
stringencies and analyzed by immunoblotting. Using
moderate stringency washing conditions of the NF45
IPs, immunoblotting demonstrated coimmunoprecipita-
tion of NF90, Ku80, Ku70 and DNA-PKcs in nuclear
extracts from NS T-cells (Figure 3, lane 3). T-cell
stimulation with PMAþionomycin (P/I) was consistently
associated with coordinate decreases in the associations of
Ku80, Ku70 and DNA-PK with NF45 (Figure 3, lane
4 versus 3). T-cells stimulated in the presence of CsA (P/I/
CsA) also showed a decrease in the associations of Ku and
DNA-PK with NF45 as in stimulated cells (Figure 3,
lane 5 versus 3), whereas T-cells stimulated in the presence
of the more potent immunosuppressant, triptolide
(P/I/Trip), showed a pattern of association of Ku and
DNA-PK with NF45 most similar to that in nonstimu-
lated cells (Figure 3, lane 6 versus 3). Under high
stringency washing conditions we observed that Ku70
and Ku80 coimmunoprecipitated with NF45 in nuclear
extracts from nonstimulated T-cells, but Ku proteins were
washed away from NF45 in extracts from stimulated
T-cells (data not shown). These results support and
complement our protein puriﬁcation results (Figure 1)
and establish that NF45, NF90, Ku70, Ku80 and DNA-
PKcs interact dynamically in the nucleus of T-cells. Our
results are supported by a recent report that used tandem
aﬃnity puriﬁcation in HEK293 cells to demonstrate
speciﬁc interactions between Ku70, Ku80 and NF90/
ILF3 (42).
Ku80,Ku70andNF90bindspecificallyanddynamicallytothe
IL-2 genepromoter in vivo, as demonstrated by chromatin
immunoprecipitation
We characterized interactions of Ku80, Ku70 and NF90
with the IL-2 promoter in resting and activated T-cells
in vivo, using formaldehyde crosslinking and chromatin
immunoprecipitation (ChIP) experiments (Figure 4). For
our ChIP studies, we designed PCR primers to interrogate
the presence of the proximal IL-2 gene promoter that
contains the ARRE/NF-AT DNA-binding sequence, and
a region within intron 3 of the IL-2 gene, 4kb removed, as
a control. The myc11 origin of DNA replication sequence
near the myc promoter, known to bind Ku80 and Ku70,
was used as a positive control, whereas the myc1 sequence,
5.9kb removed, served as a negative control (36,37). Input
chromatin prepared from nonstimulated and stimulated
Jurkat T-cells resulted in PCR ampliﬁcation products
using combinations of oligonucleotide primers for the
IL-2 intron 3, IL-2 gene promoter, myc1 and myc11
sequences (Figure 4A). Ku80 ChIP using mAB 111
showed no precipitation of IL-2 intron 3 (Figure 4B,
lanes 1 and 2), but nearly equivalent precipitation of IL-2
promoter DNA from both nonstimulated and stimulated
T-cells (Figure 4B, lanes 3 and 4). We observed identical
Ku80 ChIP results using a polyclonal antibody (data not
shown). Our Ku70 ChIP experiment showed no binding to
IL-2 intron 3 (Figure 4C, lanes 1 and 2), and speciﬁc
binding of Ku70 to the IL-2 promoter in nonstimulated
T-cells (Figure 4C, lane 3). Remarkably, T-cell stimulation
caused a substantial decrease in Ku70 binding to the IL-2
promoter (Figure 4C, lane 4). As expected, the Ku80 and
Figure 3. Association of NF45 and NF90 with Ku80, Ku70 and DNA-
dependent protein kinase is altered during T-cell activation. Jurkat
T-cells were either NS, stimulated with PMAþionomycin (P/I) for 4hr
or stimulated in the presence of CsA (P/I/CsA, 1000ng/ml) or triptolide
(P/I/Trip, 1000ng/ml). Extracted nuclear proteins (lane 1) were co-
immunoprecipitated with protein A beads (control, lane 2) or
immobilized antibody against NF45 (lanes 3–6) and the immunopre-
cipitates (IP) were washed at moderate stringency and analyzed by
Western immunoblotting. The observation of decreased association of
Ku70 and Ku80 with NF45 in activated T-cells was reproduced more
than 6 .
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was negative, while the myc11 origin sequence was
positive (Figure 4B and C, lanes 5–8). NF90 ChIP using
mAB DRBP76 showed no binding to IL-2 intron
3 (Figure 4D, lanes 1 and 2) and weak binding to the
IL-2 promoter in nonstimulated T-cells (Figure 4D, lane
3). Notably, T-cell stimulation was associated with a
substantial increase in NF90 binding to the IL-2 promoter
(Figure 4D, lane 4 versus 3). Additionally, NF90 bound
speciﬁcally to the myc11 origin sequence (Figure 4D, lanes
5–8). This is the ﬁrst evidence that NF90 binds speciﬁcally
to A-T-rich mammalian origins of DNA replication.
The changes in DNA-binding of Ku80, Ku70 and NF90
induced by T-cell stimulation occurred speciﬁcally at the
IL-2 gene promoter, and did not occur at the myc11 origin
(Figure 4B–D, lanes 7 and 8).
We performed similar ChIP experiments on primary
mouse spleen cells that were nonstimulated or stimulated
for 4hr with PMAþionomycin (Figure 4E–H). Ku70
and Ku80 bind to the adenosine deaminase (ADA) origin
of replication in vivo, and therefore we used this amplicon
as a positive control for Ku ChIP experiments in mouse
cells (37). Ku80 ChIP shows weak binding to the IL-2
promoter in nonstimulated cells (Figure 4F, lane 1) that
is induced upon stimulation (Figure 4F, lane 2 versus 1).
Ku70 ChIP shows substantial binding to the IL-2
promoter in nonstimulated cells that decreases upon
stimulation (Figure 4G, lanes 1 and 2). NF90 ChIP
shows induced binding to the IL-2 promoter upon
stimulation (Figure 4H, lane 2 versus 1). Ku80,
Ku70 and NF90 showed no binding to IL-2 intron 3
(Figure 4F–H, lanes 3 and 4), and no stimulation-induced
changes in binding to the ADA origin (Figure 4F–H, lanes
5 and 6).
Immunosuppressants cyclosporin A and triptolide inhibit
dynamicchangesinIL-2promoterbindingbyKu80andKu70
Cyclosporin A and triptolide inhibit IL-2 gene expression
at the levels of chromatin remodeling (43) and transcrip-
tional activation (41). We previously showed that tripto-
lide is more potent than CsA in its inhibition of induced
ARRE DNA-binding activity, and operates through
diﬀerent mechanisms as demonstrated by its ability to
inhibit CsA-resistant T-cell activation stimulated by
PMAþCD28 (41). We used ChIP to characterize how
CsA and triptolide aﬀected IL-2 chromatin remodeling in
Jurkat T-cells as reﬂected by dynamic changes in IL-2
proximal promoter binding by Ku80, Ku70 and NF90
(Figure 4I–K). In these experiments we observed that P/I
stimulation induced binding of Ku80 to the IL-2 promoter
(Figure 4I, lane 2 versus 1), and CsA and triptolide each
inhibited this induction (Figure 4I, lanes 3, 4 versus 2).
Reciprocally, stimulation with P/I decreased binding of
Ku70 to the IL-2 promoter (Figure 4J, lane 2 versus 1),
and CsA and triptolide each inhibited this decrease
(Figure 4J, lanes 3, 4 versus 2). Stimulation with P/I-
induced binding of NF90 to the IL-2 promoter
(Figure 4K, lane 2 versus 1), and CsA and triptolide
did not diminish this induction (Figure 4K, lanes 3,
4 versus 2). Thus, T-cell immunosuppressants that inhibit
IL-2 transcriptional activation (41) apparently operate
through mechanisms that inhibit dynamic changes in
DNA-binding of Ku80 and Ku70 to the IL-2 proximal
promoter in vivo.
DISCUSSION
In this study we present complementary experiments of
native protein puriﬁcation, EMSA-antibody inhibition
and chromatin immunoprecipitation that together demon-
strate speciﬁc and dynamic binding of purine-box
regulator subunits, Ku80, Ku70 and NF90 to the ARRE
DNA sequence in vitro and to the IL-2 proximal promoter
in vivo. These dynamic changes in binding of Ku80, Ku70
and NF90 to the IL-2 proximal promoter correlate
Figure 4. Ku80, Ku70 and NF90 bind speciﬁcally and dynamically to
the IL-2 promoter in vivo. Jurkat T-cells or mouse primary spleen cells
were NS or stimulated for 4hr with PMAþionomycin (S) then nuclear
proteins were crosslinked to chromatin in vivo with 1% formaldehyde.
(A) Sheared and restricted chromatin was used as template for PCR
ampliﬁcations (35 cycles) of IL-2 intron 3 (negative control), IL-2
proximal promoter, myc1 (negative control) and myc11 (origin of DNA
replication, positive control for Ku binding) sequences. (B) Ku80
chromatin immunoprecipitation (ChIP) was performed using mAB 111.
(C) Ku70 ChIP was performed using polyclonal antibody. (D) NF90
ChIP was performed using mAB DRBP76. (E) Input chromatin from
mouse spleen cells was used as template for ampliﬁcation of IL-2
proximal promoter, IL-2 intron 3 (negative control) and adenosine
deaminase origin of DNA replication (positive control for Ku binding).
(F) Ku80 ChIP. (G) Ku70 ChIP. (H) NF90 ChIP. (I–K) Jurkat T-cells
were NS or stimulated for 4hr with PMAþionomycin (P/I) or
stimulated in the presence of immunosuppressants cyclosporin A (P/I/
CsA) or triptolide (P/I/Trip), then IL-2 promoter ChIP was performed,
using speciﬁc antibodies against Ku80, Ku70 and NF90 and 30 cycles
of PCR ampliﬁcation.
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While Ku and DNA-PKcs are accepted to bind to
free ends of double-stranded (ds) DNA and promote
DNA repair (23,24), their functions as sequence-speciﬁc
DNA-binding proteins and transcriptional regulators
remain more ambiguous (44). An important recent study
showed that ds DNA breaks are formed during estrogen
induction of the pS2 promoter by enzymatic activity
of DNA topoisomerase IIb, and these newly formed ds
DNA breaks are repaired by Ku80, Ku70, DNA-PKcs
and poly(ADP)ribose polymerase recruited speciﬁcally to
the pS2 promoter (34). The authors proposed that
transient ds DNA break formation and DNA repair
might facilitate rapid chromatin unwinding linked to
transcriptional activation.
Ku is an abundant nuclear protein, and its aﬃnity for
free-DNA-ends creates the potential for artifacts in
EMSA experiments as a consequence of Ku binding to
the ends of linear oligonucleotide probes. In this study,
we were careful to employ suﬃcient amounts of unlabeled
competitor poly(dI-dC) as a source of free-DNA-ends
to minimize this nonspeciﬁc binding and reveal sequence-
speciﬁc binding of Ku to the radiolabeled ARRE
oligonucleotide. Sequence-speciﬁc binding of Ku to
internal A-T-rich target sequences similar to ARRE has
been demonstrated using closed DNA minicircles or
plasmids that lack free ends (28,35).
Chromatin immunoprecipitation (ChIP) allows char-
acterization of interactions between nuclear proteins and
their cognate DNA sequences in the native chromatin
context. Sequence-speciﬁc binding of Ku70 and Ku80
to A-T-rich origins of DNA replication in vivo was
demonstrated using ChIP (36,37). Rosenfeld and collea-
gues performed ChIP experiments and demonstrated
speciﬁc recruitment of Ku80, Ku70 and DNA-PK to the
pS2, Dio1, MMP12, PSA and RARb promoters upon
induction in vivo, and that activation of these promoters
was regulated through transient dsDNA break formation
and DNA repair (34).
T-cell activation is recognized to induce IL-2 chromatin
remodeling and transcriptional activation (2). The
identities of the chromatin remodeling proteins that bind
to and regulate the IL-2 proximal promoter in vivo are not
entirely clariﬁed. We isolated and characterized NF90,
NF45, Ku80 and Ku70 as speciﬁc ARRE–DNA-binding
proteins in vitro, using EMSA to monitor our biochemical
puriﬁcation under nondenaturing conditions (7,8)
(Figure 1). We now extend these ﬁndings and are the
ﬁrst to demonstrate that Ku80, Ku70 and NF90 bind
dynamically to the chromatin at the IL-2 proximal
promoter in vivo, using ChIP experiments. T-cell stimula-
tion induces binding of Ku80 and NF90 to the IL-2
promoter, and reciprocally decreases binding of Ku70
to the IL-2 promoter in vivo. The time course of dynamic
changes in binding of Ku80, Ku70 and NF90 to the IL-2
promoter correlates with induced IL-2 chromatin
remodeling in activated T-cells, assayed by micrococcal
nuclease sensitivity (45). The dynamic binding of Ku80,
Ku70 and NF90 to the IL-2 promoter during
T-cell activation is speciﬁc, as we observed no
stimulation-induced changes in the speciﬁc binding of
these proteins to myc11 or ADA origins of DNA
replication (46).
From our experiments, we propose a model for
regulation of endogenous IL-2 gene expression
(Figure 5). In nonstimulated T-cells the purine-box
regulator complex is present in the nucleus and contains
subunits Ku80, Ku70, NF90, NF45 and DNA-PKcs.
Antibodies against Ku80, Ku70 or NF90 disrupt EMSA
complex I in vitro in stimulated and nonstimulated T-cell
nuclear extracts, suggesting that these ARRE–DNA–
proteins are physically and functionally associated. ChIP
experiments demonstrate substantial binding of Ku70 to
the IL-2 promoter in nonstimulated T-cells in vivo. T-cell
activation induces conformational changes in the purine-
box regulator and IL-2 chromatin remodeling associated
with decreased binding of Ku70 and increased binding of
Ku80 and NF90 to the IL-2 promoter in vivo. A proposed
reorganization of subunits during T-cell activation that
could alter the interactions of Ku70, Ku80 and NF90 with
IL-2 promoter sequences is shown. Whether Ku70 might
completely dissociate from the IL-2 promoter and the
purine-box regulator complex during T-cell activation
in vivo remains unknown at this time.
Figure 5. Model for dynamic binding of Ku80, Ku70, NF90, NF45
and DNA-PKcs to the IL-2 proximal promoter in vivo in resting
and activated T-cells. (A) In resting T-cells, Ku70 and Ku80 bind to
the ARRE sequence in the IL-2 proximal promoter and contribute
to a closed chromatin conformation and transcriptional repression.
(B) T-cell activation induces chromatin remodeling associated with
decreased binding of Ku70 to the IL-2 promoter and increased binding
of NF90 and Ku80 to the IL-2 promoter. Associations between NF45/
NF90 heterodimer and Ku70. Ku80 and DNA-PKcs are weakened.
IL-2 chromatin remodeling is linked to the conversion of the purine-
box regulator from a transcriptional repressor into a potent transcrip-
tional activator, indicated by new interactions of transactivation (TA)
domains on NF90 and NF45 with RNA Pol II.
2308 Nucleic Acids Research, 2007, Vol. 35, No. 7We propose that increased association of NF90 and
NF45 with the chromatin at the IL-2 promoter is
associated with transcriptional activation, indicated by
transactivation (TA) domains of these proteins interacting
with RNA polymerase II. Antisera against NF45 and
NF90 speciﬁcally inhibited ARRE–DNA-binding as well
as basal and stimulated in vitro transcription (7). We
recently showed that stable overexpression of NF45 in
Jurkat T-cells conferred a 100-fold-speciﬁc increase in
ARRE/NF-AT luciferase transcriptional activation (11).
Additionally, we have observed that stable transgenic
expression of NF90 in Jurkat T-cells is associated with
70–80-fold-speciﬁc increase in ARRE/NF-AT luciferase
transcriptional activation (Shi et al, J. Exp Med. in
press). Conversely, we have determined that targeted
disruption of NF90 in mice is associated with profound
impairment of IL-2 gene expression and ARRE/NF-AT
luciferase transcriptional activation in activated T-cells
(Shi et al, J. Exp Med. in press).
Transcriptional regulation by Ku and DNA-PKcs at
speciﬁc promoters has been previously reported, with
suggestions of opposing roles for Ku70 and Ku80 (25–34).
For example, Ku and DNA-PKcs mediated inhibition
of RNA Pol II transcription at the hsp70 promoter (27)
and at the NRE1 site in the mouse mammary tumor virus
promoter (28). Inhibitory eﬀects of Ku on transcription
correlated with the level of expression of Ku70
protein: (i) transgenic overexpression of Ku70 protein
in rat ﬁbroblasts suppressed the induction of hsp70
in response to heat shock (47) and (ii) in mouse
lymphosarcoma cells, heat shock was associated with a
rapid disappearance of Ku70 protein (48). A transcrip-
tional activating role for Ku80 was suggested by (i)
the report that transfection of a Ku80 expression
plasmid into Ku80-deﬁcient MCF-7 breast cancer cells
activated transcription of a human glucocorticoid
receptor reporter gene (26), (ii) the result that rat
ﬁbroblasts which overexpressed Ku80 showed enhanced
induction of hsp70 in response to heat shock (47) and (iii)
in vitro transcription studies that demonstrated speciﬁc
enhancement of hsp70 promoter transcriptional initiation
associated with expression of Ku80 cDNA in xrs-6 Ku80-
deﬁcient cells (49).
Our results suggest novel and important roles for Ku80,
Ku70, NF90 and NF45 in the regulation of IL-2 chromatin
remodelingandgeneexpressioninactivatedT-cells.Future
investigations should elucidate how Ku80 and Ku70
may serve reciprocal roles in regulating IL-2 chromatin
remodeling and gene expression in activated T-cells.
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